A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs INCB 057643 (Primary) ; Abiraterone; Azacitidine; Gemcitabine; Paclitaxel; Rucaparib; Ruxolitinib
  • Indications Haematological malignancies; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 12 Dec 2017 Preliminary results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 27 Nov 2017 Study protocol has been amended for this trial and multiple fields in the profile are changed.Purpose has been modified 2 additional parts are included part III and IV in which INCB057643 will be tested along with SOCs. Primary end point is changed. No. of treatment arm changed from 1 to 2. Patient number significantly changed from 230 to 420. I have also received confirmation from an investigator (Phalden@incyte.com) about the same.
    • 27 Nov 2017 Planned number of patients changed from 230 to 420.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top